Flagship Harbor Advisors LLC Purchases Shares of 6,303 Exelixis, Inc. (NASDAQ:EXEL)

Flagship Harbor Advisors LLC bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 6,303 shares of the biotechnology company's stock, valued at approximately $233,000.

A number of other large investors also recently made changes to their positions in the business. Invesco Ltd. raised its holdings in shares of Exelixis by 308.1% during the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock worth $132,376,000 after acquiring an additional 3,001,204 shares in the last quarter. Norges Bank acquired a new position in Exelixis in the 4th quarter worth about $94,867,000. Caisse DE Depot ET Placement DU Quebec raised its stake in shares of Exelixis by 330.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company's stock worth $82,730,000 after purchasing an additional 1,907,167 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Exelixis by 104.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company's stock worth $105,208,000 after purchasing an additional 1,613,482 shares in the last quarter. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Exelixis during the 4th quarter valued at about $30,321,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of research reports. Guggenheim set a $45.00 price objective on Exelixis and gave the stock a "buy" rating in a report on Thursday, May 15th. UBS Group reissued an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the stock a "buy" rating in a research note on Tuesday. Wall Street Zen lowered shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 15th. Finally, HC Wainwright reiterated a "buy" rating and issued a $47.00 price objective (up from $40.00) on shares of Exelixis in a report on Thursday, June 12th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.22.

Exelixis Trading Up 1.3%

EXEL traded up $0.58 during midday trading on Friday, reaching $43.67. The company's stock had a trading volume of 3,523,886 shares, compared to its average volume of 2,445,305. The company has a fifty day simple moving average of $40.92 and a 200 day simple moving average of $37.27. The stock has a market cap of $11.91 billion, a P/E ratio of 19.85, a PEG ratio of 0.87 and a beta of 0.28. Exelixis, Inc. has a twelve month low of $21.82 and a twelve month high of $49.62.

Insider Transactions at Exelixis

In other news, EVP Dana Aftab sold 1,508 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $39.00, for a total transaction of $58,812.00. Following the transaction, the executive vice president now owns 693,181 shares in the company, valued at approximately $27,034,059. The trade was a 0.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jack L. Wyszomierski sold 7,535 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total transaction of $324,683.15. Following the transaction, the director now directly owns 358,882 shares of the company's stock, valued at $15,464,225.38. This represents a 2.06% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 458,113 shares of company stock worth $21,024,817 over the last three months. 2.82% of the stock is currently owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.